Research Article
Significance of PPARA as a Treatment Target for Chronic Lymphocytic Leukemia
Table 1
Characteristics of 86 newly diagnosed chronic lymphoblastic leukemia patients.
| Characteristics | N (%) |
| Sex | | Male | 61 (70.93%) | Female | 25 (29.07%) | Age (year) | | <45 | 9 (10.46%) | ≥45, <65 | 51 (59.30%) | ≥65 | 26 (30.23%) | CLL-IPI | | Low/intermediate risk | 74 (86.05%) | High risk | 12 (13.95%) | FISH | | del(13q) | 12 (13.95%) | del(11q) | 13 (15.11%) | del(17p) | 5 (5.81%) | Trisomy 12 | 2 (2.32%) | TP53(NGS) | | TP53 mutation | 5 (5.81%) | TP53 wt | 78 (90.70%) | Unknown | 3 (3.49%) | IGHV | | Mutated | 61 (70.93%) | Unmutated | 25 (29.07%) | Bulky disease | 9 (10.465%) | Extranodal involvement | 5 (5.814%) | Hepatomegaly | 5 (5.814%) | Splenomegaly | 42 (48.837%) | Initial WBC (×109/L) | | >100 | 3 (3.488%) | 50–100 | 15 (17.442%) | <50 | 68 (79.07%) | Initial HGB (g/L) | | >110 | 69 (80.233%) | 90–110 | 11 (12.791%) | <90 | 6 (6.977%) | Initial PLT (×109/L) | | ≥100 | 77 (89.535%) | <100 | 9 (10.465%) | Initial LYM (%) | | >80 | 44 (51.163%) | 50–80 | 31 (36.047%) | <50 | 11 (12.791%) | Initial LYMC (×109/L) | | >100 | 3 (3.488%) | 50–100 | 8 (9.302%) | <50 | 75 (87.209%) |
|
|